Vir Biotechnology (NASDAQ:VIR) CAO Brent Sabatini Sells 1,430 Shares

Vir Biotechnology, Inc. (NASDAQ:VIR) CAO Brent Sabatini sold 1,430 shares of the firm’s stock in a transaction that occurred on Tuesday, February 24th. The stock was sold at an average price of $9.53, for a total transaction of $13,627.90. Following the completion of the transaction, the chief accounting officer directly owned 69,613 shares in the company, valued at $663,411.89. This trade represents a 2.01% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Brent Sabatini also recently made the following trade(s):

• On Monday, February 23rd, Brent Sabatini sold 1,829 shares of Vir Biotechnology stock. The shares were sold at an average price of $7.45, for a total transaction of $13,626.05.
• On Friday, February 13th, Brent Sabatini sold 1,530 shares of Vir Biotechnology stock. The shares were sold at an average price of $7.79, for a total transaction of $11,918.70.

Vir Biotechnology Price Performance

Shares of VIR stock traded down $0.23 during trading on Friday, hitting $9.09. 719,863 shares of the stock traded hands, compared to its average volume of 3,674,494. Vir Biotechnology, Inc. has a 52-week low of $4.16 and a 52-week high of $10.94. The firm has a market capitalization of $1.27 billion, a P/E ratio of -2.89 and a beta of 1.69. The firm’s fifty day moving average price is $6.95 and its 200-day moving average price is $6.04.

Vir Biotechnology (NASDAQ:VIR) last released its quarterly earnings results on Monday, February 23rd. The company reported ($0.31) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.42) by $0.11. The business had revenue of $64.07 million during the quarter, compared to analysts’ expectations of $19.91 million. Vir Biotechnology had a negative return on equity of 49.31% and a negative net margin of 638.88%.The company’s revenue was up 417.8% compared to the same quarter last year. During the same period in the prior year, the business posted ($0.76) EPS. As a group, equities research analysts expect that Vir Biotechnology, Inc. will post -3.92 earnings per share for the current year.

Institutional Trading of Vir Biotechnology

Hedge funds and other institutional investors have recently bought and sold shares of the company. Mirae Asset Global Investments Co. Ltd. lifted its stake in shares of Vir Biotechnology by 25.9% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 6,761 shares of the company’s stock worth $41,000 after purchasing an additional 1,390 shares during the period. FNY Investment Advisers LLC acquired a new position in shares of Vir Biotechnology in the 3rd quarter valued at $38,000. Raymond James Financial Inc. purchased a new stake in shares of Vir Biotechnology during the 2nd quarter valued at $35,000. UMB Bank n.a. increased its holdings in shares of Vir Biotechnology by 1,418.7% during the 4th quarter. UMB Bank n.a. now owns 7,062 shares of the company’s stock worth $43,000 after buying an additional 6,597 shares during the last quarter. Finally, Federated Hermes Inc. raised its position in shares of Vir Biotechnology by 153.8% in the 3rd quarter. Federated Hermes Inc. now owns 8,085 shares of the company’s stock worth $46,000 after buying an additional 4,899 shares during the period. 65.32% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of brokerages recently weighed in on VIR. Needham & Company LLC lifted their price objective on shares of Vir Biotechnology from $14.00 to $18.00 and gave the company a “buy” rating in a report on Tuesday. HC Wainwright restated a “buy” rating and issued a $15.00 target price on shares of Vir Biotechnology in a report on Tuesday, December 30th. Raymond James Financial raised shares of Vir Biotechnology from an “outperform” rating to a “strong-buy” rating and set a $19.00 target price on the stock in a report on Tuesday. Barclays boosted their price target on shares of Vir Biotechnology from $26.00 to $30.00 and gave the stock an “overweight” rating in a research note on Tuesday. Finally, Evercore restated an “outperform” rating and issued a $18.00 price target on shares of Vir Biotechnology in a report on Tuesday. One equities research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $19.89.

Trending Headlines about Vir Biotechnology

Here are the key news stories impacting Vir Biotechnology this week:

• Positive Sentiment: Astellas strategic collaboration with Vir on the prostate‑cancer asset (VIR‑5500) includes up‑front/near‑term payments and up to about $1.7 billion in contingent milestones — a material de‑risking and commercialization path for a late‑stage asset. Read More.
• Positive Sentiment: Quarterly results beat expectations: Q4 revenue (~$64M) and EPS topped consensus, signaling improving commercial traction and supporting higher analyst enthusiasm. Read More.
• Positive Sentiment: Analyst upgrades and target increases followed the news (Needham raised its target to $18), boosting upside sentiment despite current volatility. Read More.
• Neutral Sentiment: Management will present at investor conferences in early March (TD Cowen, Leerink), which can provide clarity but are not a fundamental catalyst by themselves. Read More.
• Neutral Sentiment: Comparative coverage and peer analyses are increasing visibility and trading volume (e.g., head‑to‑head pieces with peers), but they don’t change Vir’s underlying cash flow or pipeline. Read More.
• Negative Sentiment: Vir priced an underwritten offering of 17,647,058 shares at $8.50 (~$150M gross proceeds). The discounted placement strengthens the balance sheet but is dilutive and increases near‑term share supply, pressuring the stock. Read More.
• Negative Sentiment: Coverage noted the discounted offering as the proximate cause of the post‑rally pullback/tumble, amplifying short‑term selling. Read More.
• Negative Sentiment: Significant insider selling was disclosed (multiple officers and a director reported sales last week), which—combined with the offering—added visible supply and negative sentiment. Read More.

Vir Biotechnology Company Profile

Vir Biotechnology, Inc is a clinical‐stage immunology company dedicated to developing therapies that prevent and treat serious infectious diseases. The company leverages a suite of proprietary technology platforms—ranging from antibody isolation and screening tools to cell‐based assays and bioinformatics—to identify and advance antiviral and antibacterial candidates. Its scientific approach centers on harnessing the human immune system through monoclonal antibodies and immunomodulatory agents.

The company’s pipeline includes product candidates targeting influenza A, COVID‐19, HIV, hepatitis B, and tuberculosis.